Background: Tolvaptan has been reported to be effective for treating acute decompensated heart failure and chronic heart failure. Whether it is also effective for treating chronic heart failure, however, remains unclear. We therefore aimed to assess the efficacy of tolvaptan in patients with chronic heart failure and chronic kidney disease. Methods: We examined the change of such parameters as estimated glomerular filtration rates, BNP levels, serum sodium concentration levels, and loop diuretic doses before and six months after the initiation of tolvaptan therapy in nine patients with chronic heart failure and chronic kidney disease. Prior to the initiation of tolvaptan therapy, all the nine patients were hyponatremic and hypotensive, with New York Heart Association class II or III heart failure, receiving a dose of more than or equal 60 mg furosemide per day. Results: The loop diuretic doses and BNP levels six months after the initiation of tolvaptan therapy were both significantly lower than those before the initiation of tolvaptan therapy (27.8 ± 4.4 mg vs 81.1 ± 41.1 mg, P = .002 and 779 ± 1218 pg/mL vs 1104 ± 1305 pg/mL, P = .0298, respectively). Conclusion: Tolvaptan therapy may contribute to reduce the loop diuretic doses and lower BNP levels in patients with chronic kidney disease and chronic heart failure.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect